(ABBI) Abraxis received two FDA Approvals for Fludarabine Phosphate as cancer drugs.
(ABT) Abbott Labs $0.67 EPS vs $0.66 est.
(ALGN) Align Tech traded up on positive Cramer comments on Mad Money.
(ASYS) Amtech Systems announced $17.4 million in new solar orders; selling $34 million in stock.
(BMY) Bristol-Myers Squibb won FDA approval for Ixempra breast cancer drug for those who have stopped responding to other treatment.
(CIT) CIT Group $1.29 EPS vs $1.24 est.
(CMA) Comerica $1.17 EPS vs $1.22 est.
(CSX) CSX $0.67 EPS vs $0.62 est.
(DLR) Digital Realty Trust priced 3.5 million shares at $39.38 in secondary offering.
(EXAS) EXACT Sciences received Warning Letter from FDA; stock indicated down 10% or more.
(IBM) IBM trading down almost 1% after slightly beating estimates.
(IMCL) ImClone and Bristol-Myers enter pact with Merck KGaA to co-develop ERBITUX in Japan.
(INTC) Intel trading up 5% after beating earnings and raised guidance.
(JPM) JPMorgan Chase $0.97 vs $0.90 est.
(KO) Coca-Cola $0.71 EPS vs $0.68 est.
(LLTC) Linear Tech $0.40 EPS vs $0.38 est.
(MAN) Manpower raised guidance.
(MLAN) Midland gets $65 buyout from Munich RE.
(MO) Altria $1.21 EPS vs $1.14 est.; slightly raised guidance.
(NITE) Knight Trading $0.09 EPS vs $0.12 est.
(PHHM) Palm Harbor -$0.10 EPS vs -$0.05 est.
(SNCI) Sonic traded up on Cramer positive feature on mad Money.
(STX) Seagate traded up almost 2% after beating earnings.
(UTX) United Tech $1.21 EPS vs $1.16 est.
(WBMD) WebMD lowered guidance; stock indicated down as much as 8%.
(YHOO) Yahoo! trading up 9% after beating earnings.
Jon C. Ogg
October 17, 2007